Your Gateway to America's Market and Global Opportunities

Your Company Could Be Here

Global Exposure. Real Business Results.

Advertise with ATN

Reshoring and New Factories: Latest Plant Announcements in North America

Reshoring and New Factories: Latest Plant Announcements in North America

ATN BREAKING NEWS |

Reshoring and New Factories: Latest Plant Announcements in North America

October 27, 2026 | ATN Trade & Finance


The factory investment wave that began with the CHIPS and Science Act in 2022 and the Inflation Reduction Act's clean energy incentives has not slowed — it has broadened. Approximately $1.6 trillion in manufacturing commitments have been announced in the United States since the post-COVID policy shift began, covering semiconductors, pharmaceuticals, clean energy, automotive, and defense. The past three months have added dozens of new projects to that ledger. Here is a current accounting of the most significant announced and ongoing plant investments across North America and what they signal about the reshoring trend's direction.

Semiconductors: Groundbreakings and Production Starts

The headline semiconductor event of the year was Micron Technology's January 16 groundbreaking in Clay, New York — a $100 billion commitment to build what it calls the largest semiconductor facility in the United States. Located in Onondaga County in Central New York, the facility is expected to create 9,000 on-site jobs, support up to 50,000 regional jobs over 30 years, and generate $9.5 billion in annual regional economic output starting in 2027. Micron is targeting advanced memory chips for AI data centers as the facility's primary purpose.

In Sherman, Texas, GlobalWafers reached a production milestone in February 2026 when Phase II operations began at its $4 billion silicon wafer plant — part of a $7.5 billion regional investment backed by $400 million in CHIPS Act funding. The plant targets production of up to 1.2 million 12-inch wafers per month, supplying substrate material to customers including Texas Instruments and TSMC. Approximately 1,500 jobs are expected at full build-out.

In California, Bosch announced in July a facility in Roseville of up to $2 billion to manufacture silicon carbide semiconductors on 200mm wafers, backed by up to $225 million in CHIPS Act support. The plant would supply over 40% of US silicon carbide device capacity — a material critical to power electronics in electric vehicles and industrial equipment — and is expected to create 700 jobs.

Automotive: Toyota Moves Tacoma Production Out of Mexico

The automotive announcement that most directly illustrates the reshoring dynamic came in July, when Toyota announced a $3.6 billion expansion of its San Antonio, Texas plant to add a second assembly line for the Tacoma pickup truck. The expansion will move most Tacoma production from Toyota's Baja California facility in Mexico to Texas, add 2.5 million square feet to the campus, and create 2,000 new US jobs, with construction continuing through 2030. The decision is directly tied to the tariff environment: the 25% Section 232 auto tariff and the risk of additional USMCA-related costs on Mexican production made the economics of domestic manufacturing more competitive.

Power Infrastructure: Transformers and Electrical Equipment

The AI data center buildout and industrial electrification have driven a wave of investment in grid infrastructure components. Hitachi Energy is investing $528 million in a transformer manufacturing plant in Gallman, Mississippi, which will employ over 700 people when it opens (targeted for 2029). The transformer shortage — driven by surging demand from data centers, EV charging infrastructure, and the general grid modernization — has made domestic transformer capacity a strategic priority for utilities and the federal government.

In Jackson County, Georgia, Siemens announced a $185 million expansion of low-voltage electrical component manufacturing, creating over 1,400 jobs. In North Little Rock, Arkansas, Eaton's Fibrebond unit is investing more than $242 million in modular electrical enclosure manufacturing, creating more than 1,200 jobs. And in San Antonio, Texas, IEM (Industrial Electric Manufacturing) is building a $200 million facility for custom power distribution and control systems, with a capacity to grow to 3,000 jobs by 2030.

Clean Energy: Solar, Batteries, and Fuel Cells

The clean energy manufacturing buildout that began with IRA incentives continued through Q3. In Laurens County, South Carolina, Suniva raised $835 million — with approximately $600 million earmarked for a 4.5 gigawatt solar cell manufacturing facility — and expects to create 564 jobs. In Houston, SEG Solar opened a 4 gigawatt solar module facility representing a $200 million investment and up to 800 jobs. In Monroe, Georgia, DeltaX committed $141 million to manufacture battery energy storage systems, creating approximately 250 jobs. Bloom Energy's results reported this week — revenue up 138% year-over-year to $1.235 billion in Q3 — underscore that the clean power manufacturing build is generating real revenue, not just announced intentions.

Pharmaceuticals: API, Injectable Devices, and OTC Products

The pharmaceutical manufacturing pipeline has quietly become one of the most active reshoring sectors. Octapharma is investing $1.5 billion to build a plasma-derived therapy manufacturing plant in Rock Hill, South Carolina, expected to employ approximately 1,500 workers. Resilience and Eli Lilly announced a $750 million facility in the Cincinnati, Ohio region to manufacture KwikPen injectable devices for GLP-1 medicines, employing over 400 people. STERIS is investing $600 million in Sanford, North Carolina, for infection prevention chemical manufacturing, employing roughly 335 workers. Genentech (Roche) is putting up approximately $750 million in Hillsboro, Oregon, for a device fill-finish facility producing pre-filled syringes and autoinjectors, with commercial operations expected in 2031.

The Macro Picture

The Reshoring Initiative's most recent full-year data shows 244,000 announced manufacturing jobs reshored or brought in via foreign direct investment in 2024 — down from the 2022 record of 364,000 but still a historically elevated level. Semiconductors and electronics accounted for 35% of 2024 announcements; electrical equipment, including EV batteries and solar components, accounted for another 31%. High-tech and medium-high-tech manufacturing made up 88% of the total, reflecting the concentration of incentive programs and supply chain risk concerns in advanced manufacturing rather than consumer goods.

The execution gap is real and well-documented: semiconductor fabs take roughly nine years from announcement to full employment. Only about 2% of companies with formal reshoring plans have fully completed them, according to one survey. But the pipeline itself — roughly $1.6 trillion in total announced commitments — is large enough that even a fraction of execution represents a structural shift in North American manufacturing geography.


What this means: The reshoring trend is no longer being driven primarily by policy incentives alone. The Section 232 tariffs on steel, aluminum, and automobiles, the USMCA review uncertainty around Mexican content, and the escalating tariff environment with Canada have all made domestic production economics more competitive across a wider range of industries than the CHIPS Act or IRA were designed to reach. Toyota's Tacoma decision is the clearest example: a direct production transfer from Mexico to Texas, driven by tariff arithmetic rather than subsidy capture. The power infrastructure wave — transformers, switchgear, and electrical enclosures — is driven by the data center buildout and grid electrification demand, and it is bringing manufacturing employment to states that have not historically been industrial centers. The common thread is that the reshoring pipeline is now large enough, and diversified enough across sectors, that it will continue even if specific policies change — because the underlying demand drivers, from AI infrastructure to energy transition to pharmaceutical supply chain security, are structural rather than cyclical.


Sources:

Leave a comment